- This topic is empty.
-
Posts
-
Explore the essential regulatory changes under the New Drugs and Clinical Trials (NDCT) Amendment Rules 2026. Learn how these crucial updates impact clinical research, reduce statutory review timelines from 90 to 45 working days, replace test licenses with streamlined prior intimation mechanisms for low-risk categories, and affect bioequivalence studies. Discover how pharmaceutical and biotech companies can navigate CDSCO portal compliance, optimize drug development life cycles, accelerate commercial market entry in India, and maintain rigorous Good Clinical Practice (GCP) quality standards. Stay ahead of evolving compliance mandates, streamline your regulatory submission processes, and build operational resilience by understanding these landmark 2026 policy reforms designed to foster innovation, transparency, and trust-based regulatory oversight across the entire Indian pharmaceutical and clinical research ecosystem.
